Journal of Antimicrobial Chemotherapy (1999) 43, 777-782
© 1999 The British Society for Antimicrobial Chemotherapy
Differences between the activity of penicillin, amoxycillin, and co-amoxyclav against 5,252 Streptococcus pneumoniae isolates tested in the Alexander Project 1992- 1996
a Anti-Infectives , SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA; b Department of Biostatistics and Data Sciences, SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA; c GR Micro Ltd., London, UK
A number of published studies have shown that the MICs of amoxycillin and/or co-amoxyclav are lower than those of ampicillin and/or penicillin for Streptococcus pneumoniae. Other published studies have concluded that the activities of amoxycillin and co-amoxyclav are comparable with that of penicillin for S. pneumoniae. A collection of 5252 S. pneumoniae isolates obtained during a 5 year period (1992- 1996) was analysed to determine differences between the MICs of penicillin, amoxycillin and co-amoxyclav. Among the isolates analysed, 3788 (72%) were penicillin-susceptible, 615 (12%) were penicillin-intermediate and 849 (16%) were penicillin-resistant. Differences between the agents were assessed by examination of MIC distribution functions and simultaneous 95% CIs. In addition, penicillin-intermediate and -resistant isolates were analysed to determine the number and percentage of isolates which had an amoxycillin and co-amoxyclav MIC less than, equal to, or greater than the penicillin MIC. Results showed that the amoxycillin and co-amoxyclav MIC 90s were one two-fold dilution lower than those of penicillin for all isolates collected between 1992- 1993 and 1994- 1996. Simultaneous 95% CIs showed that the mean differences between MICs of amoxycillin and penicillin, and between MICs of co-amoxyclav and penicillin, were less than zero. The majority of the penicillin-intermediate and penicillin-resistant isolates had an amoxycillin and co-amoxyclav MIC less than the penicillin MIC. In conclusion, amoxycillin and co-amoxyclav MICs were shown to be lower than the penicillin MICs for the S. pneumoniae isolates analysed in this study.
* Corresponding address. SmithKline Beecham Pharmaceuticals, 1250 S. Collegeville Road, UP1340, PO Box 5089, Collegeville, PA 19426-0989, USA. Tel: +1-610-917-6278; Fax: +1-610-917-4617
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Finlay, L. Miller, and J. A. Poupard A review of the antimicrobial activity of clavulanate J. Antimicrob. Chemother., July 1, 2003; 52(1): 18 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. du Plessis, E. Bingen, and K. P. Klugman Analysis of Penicillin-Binding Protein Genes of Clinical Isolates of Streptococcus pneumoniae with Reduced Susceptibility to Amoxicillin Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2349 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Felmingham, Y. Tesfaslasie, C. Burley, and R. G. Masterton Penicillin resistance in pneumococci J. Antimicrob. Chemother., May 1, 2000; 45(5): 710 - 711. [Full Text] [PDF]
|
|